Acelyrin (SLRN) Company Overview

NEW YORK , Feb. 6, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Acelyrin, Inc. (Nasdaq: SLRN ), relating to the proposed merger with Alumis Inc. Under the terms of the agreement, Acelyrin stockholders will receive 0.4274 shares of Alumis common stock per share of common stock owned.

Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026

Acelyrin, Inc. shifts focus to developing lonigutamab for thyroid eye disease, aiming for phase 3 trials in Q1 2025, bypassing phase 2b/3 studies. Key catalysts include an end-of-phase 2 meeting and additional phase 2 data by the end of 2024, potentially boosting shareholder value. Lonigutamab offers a competitive edge with subcutaneous administration, higher potency, and lower adverse events compared to other anti-IGF-1R therapies.

ACELRYN, INC. (Nasdaq: SLRN), a biopharmaceutical company specializing in advancing innovative medicines in immunology, will hold a conference call on Monday, May 13, 2024 at 4:30 p.m. ET to review its financial results for the first quarter of 2024 and give a corporate update.

ACELYRIN (SLRN) posts positive proof-of-concept data from a phase I/II study evaluating its pipeline candidate, lonigutamab, for treating thyroid eye disease. Stock gains.

Acelyrin Inc shares slid as much as 11% in pre-market trading on Tuesday after the late-stage clinical biopharma company disclosed a programming error in its Phase 2b/3 drug trial for izokibep, a treatment for psoriatic arthritis.    Acelyrin said the protocol was programmed incorrectly by a vendor, "resulting in a sequencing error that went further unidentified through the providers' testing processes.

Acelyrin Inc. (NASDAQ:SLRN ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Tyler Marciniak - Vice President, Investor Relations, Communications, Corporate Operations Shao-Lee Lin - Founder, Chief Executive Officer and Director Gil Labrucherie - Chief Financial Officer Conference Call Participants Yasmeen Rahimi - Analyst, Piper Sandler Emily Bodnar - Analyst, H.C. Wainwright and Company Akash Tewari - Analyst, Jefferies Tyler Van Buren - TD Cowen Vikram Purohit - Morgan Stanley Operator Good day, and thank you for standing by.

Acelyrin's izokibep failed to meet statistical significance in its primary endpoint in a clinical trial evaluating the drug for the treatment of a skin inflammatory disorder. Shares of the biopharma company fell more than 50%, wiping out all of its post-IPO gains.

ACELYRIN (SLRN) fails to achieve statistically significant primary endpoint result in the hidradenitis suppurativa study of its lead candidate, izokibep. The stock of the company falls 54%.